During the corresponding time, Harrow Inc recorded a revenue increase by 11.26 % year on year, sequentially revenue grew by 60.43 %. While revenue at the Harrow Inc 's corporate clients
Harrow Inc's Comment on Sales, Marketing and Customers
The company serves over 10,000 U.S. eyecare prescribers and institutions. It operates two compounding facilities in Ledgewood, New Jersey, producing compounded pharmaceutical products within the United States. Its markets include pharmaceutical compounding for patients requiring customized formulations when commercially available products do not meet clinical needs. The company holds ownership and royalty interests in pharmaceutical companies pursuing drug approvals, including Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. Melt Pharmaceuticals focuses on sedation and anesthesia therapeutics for hospital, outpatient, and in-office medical procedures, targeting human medical procedures that require regulatory approval and reimbursement coding. Customers and markets identified in company filings include Eton Pharmaceuticals, Inc., Melt Pharmaceuticals, Inc., and Surface Ophthalmics, Inc.
In a move that could significantly impact the accessibility of ophthalmic treatments, Harrow (NASDAQ: HRRO) has recently introduced their Harrow Access for All (HAFA) initiative. This groundbreaking program is designed to enhance market access for their innovative portfolio of ophthalmic products, making essential treatments more readily available to patients who need them the most. Expanding the Horizon of Ophthalmic CareHarrow, known for its commitment to innovation and patient care, aims to leverage the HAFA initiative to streamline market access for its entire range of ophthalmic offerings. The company s vision is clear: to eliminate barriers that hinder patient access to vital treatments while addressin...
Harrow Reports Q1 2025 Financial Results Amid Ongoing Investor Engagement NASHVILLE, Tenn. Harrow Health, Inc. (NASDAQ: HROW), a prominent player in the North American eyecare pharmaceutical space, has announced its financial results for the first quarter ended March 31, 2025. This update continues to underscore the company s commitment to maintaining transparency with its stakeholders as it navigates a competitive market and positions itself for future growth.In its Q1 report, Harrow highlighted its strategic initiatives aimed at strengthening its product pipeline and enhancing shareholder value. The company has posted its quarterly financial results along with a detailed letter to stockholders and a cor...
Expanding Access and Affordability: Harrow s Innovative Initiative in Eyecare Pharmaceuticals In recent years, the rising cost of prescription medications has been a major concern among patients, healthcare providers, and policymakers alike. Addressing these concerns requires innovative solutions from pharmaceutical companies willing to rethink traditional pricing strategies and partnerships. One such company, Harrow (Nasdaq: HROW), a prominent North American eyecare pharmaceutical firm, has taken significant strides toward reshaping the landscape of ophthalmic pharmaceuticals through a new access and affordability program. This initiative, announced in Nashville, Tennessee, is poised to revolutionize the wa...
Harrow Inc. Revives TRIESENCE: A Steady Step Forward in Ocular Treatments In a significant development for the ophthalmic pharmaceutical landscape, Harrow Inc. (Nasdaq: HROW), a prominent North American eyecare pharmaceutical company, has announced the relaunch of TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL. This preservative-free synthetic corticosteroid, approved by the U.S. Food and Drug Administration (FDA), stands out for its dual application: enhancing visualization during vitrectomy and treating ocular inflammatory conditions that resist traditional topical corticosteroids.The TRIESENCE relaunch reflects Harrow s commitment to improving patient outcomes and maintaining a strong ...
Harrow Inc’s Comment on Sales, Marketing and Customers
The company serves over 10,000 U.S. eyecare prescribers and institutions. It operates two compounding facilities in Ledgewood, New Jersey, producing compounded pharmaceutical products within the United States. Its markets include pharmaceutical compounding for patients requiring customized formulations when commercially available products do not meet clinical needs. The company holds ownership and royalty interests in pharmaceutical companies pursuing drug approvals, including Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. Melt Pharmaceuticals focuses on sedation and anesthesia therapeutics for hospital, outpatient, and in-office medical procedures, targeting human medical procedures that require regulatory approval and reimbursement coding. Customers and markets identified in company filings include Eton Pharmaceuticals, Inc., Melt Pharmaceuticals, Inc., and Surface Ophthalmics, Inc.
Sources:
Harrow Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Harrow Inc’s corporate clients.
For your research, we’ve provided 9 tables on Harrow Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
162.33 %